# US 2020/0138904 A1 · Methods for Generation of Cell-derived Microfilament Network

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138904 A1
- Document ID: US20200138904A1
- Status: Published application
- Kind: A1
- Application number: 16/074,539
- Filed: 2018-04-13
- Published: 2020-05-07
- Earliest claimed: 2017-04-14
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Tingfang Yi; Gerhard Wagner
- Web page: https://patentgrep.com/patent/US20200138904A1

## CPC

- A61K 38/1719: {Muscle proteins, e.g. myosin or actin}
- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- A61L 27/36: containing ingredients of undetermined constitution or reaction products thereof {, e.g. transplant tissue, natural bone, extracellular matrix (isolated natural compounds, e.g. collagen A61L27/24)}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- A61L 27/60: Materials for use in artificial skin
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides for a network of cell-derived microfilaments. Also provided are methods of producing a network of microfilaments via culturing cells in a matrix support and cell culture medium wherein the cells proliferate and form aggregated cell masses, which produce microfilaments external to and surrounding the cell masses, and wherein the extracellular microfilaments connect and form a continuous extracellular microfilament network, and methods for treating a medical condition as well as facilitating wound repair and tissue regeneration comprising applying the microfilament network to an area in need of treatment.

## Claims

### Claim 1

A network comprising cell-derived microfilaments interconnected in a continuous lattice or mesh structure between a plurality of microfilament source regions.

### Claim 2 (depends on 1)

The network of claim 1 wherein the microfilaments are extracellular microfilaments.

### Claim 3 (depends on 1)

The network of claim 1 wherein the microfilaments are membrane-enclosed.

### Claim 4 (depends on 1)

The network of claim 1 wherein the microfilaments comprise actin.

### Claim 5 (depends on 4)

The network of claim 4 wherein the actin comprises β-actin.

### Claim 6 (depends on 1)

The network of claim 1 wherein the microfilaments are about 1-1000 μm in length.

### Claim 7 (depends on 1)

The network of claim 1 wherein the microfilaments are.

### Claim 8 (depends on 7)

The network of claim 7 wherein the microfilaments have about 2-10 branches.

### Claim 9 (depends on 1)

The network of claim 1 wherein multiple microfilaments align together and form bundles of diverse architectural structures.

### Claim 10 (depends on 1)

The network of claim 1 wherein the microfilament source regions form connection nodes for the continuous lattice or mesh structure.

### Claim 11 (depends on 1)

The network of claim 1 further comprises adhesive materials.

### Claim 12 (depends on 11)

The network of claim 11 wherein the adhesive materials associate with the microfilaments and enlarge the diameter of the microfilaments.

### Claim 13 (depends on 1)

The network of claim 1 wherein the network has an area in the range of about 1 μm2 to about 500 cm2 and a thickness in the range of about 1 nm to about 0.5 cm.

### Claim 14 (depends on 1)

The network of claim 1 wherein the network is single or multiple layered.

### Claim 15 (depends on 1)

The network of claim 1 wherein the surface area of the microfilaments is greater than an equivalent unit of an intra-cellular cytoskeletal microfilament network surface area.

### Claim 16 (depends on 1)

The network of claim 1 wherein the network is porous.

### Claim 17 (depends on 16)

The network of claim 16 wherein the pore size ranges from about 0.1-5 μm in diameter.

### Claim 18 (depends on 1)

The network of claim 1 further comprising bioactive and/or bioinactive agents.

### Claim 19 (depends on 18)

The network of claim 18 wherein the bioactive agents are therapeutic drugs.

### Claim 20 (depends on 1)

The network of claim 1 wherein the microfilament source regions include cells.

### Claim 21 (depends on 1)

The network of claim 1 wherein the network is present on a matrix support, wherein the matrix support is biodegradable.

### Claim 22 (depends on 1)

The network of claim 1 wherein the network is present on a Matrigel matrix support.

### Claim 23 (depends on 1)

The network of claim 1 wherein the network lacks nuclei from cells.

### Claim 24 (depends on 1)

The network of claim 1 wherein the network lacks cells.

### Claim 25 (depends on 1)

The network of claim 1 wherein the microfilament source regions include eukaryotic cells with or without genetic modification.

### Claim 26 (depends on 25)

The network of claim 25 wherein the eukaryotic cells comprise mammalian cells.

### Claim 27 (depends on 26)

The network of claim 26 wherein the mammalians cells comprise human cells.

### Claim 28 (depends on 27)

The network of claim 27 wherein the human cells comprise human mammary epithelial cells.

### Claim 29 (depends on 1)

The network of claim 1 wherein the microfilaments are embedded within the top surface of the matrix support.

### Claim 30 (depends on 1)

The network of claim 1 wherein the matrix support inhibits cell attachment and migration.

### Claim 31 (depends on 1)

A method of producing a network of microfilaments of claim 1 comprising the steps of:
culturing cells in a matrix support and cell culture medium wherein the cells proliferate and form aggregated cell masses, and wherein the cell masses produce microfilaments external to and surrounding the cell masses, and wherein the extracellular microfilaments connect and form a continuous extracellular microfilament network, and
removing nuclei of the cells and/or the cells from the network.

### Claim 32 (depends on 31)

The method of claim 31 wherein the cell masses form on top of the matrix support.

### Claim at position 33

-58. (canceled)

### Claim 59 (depends on 1)

A method for treating a medical condition comprising applying the microfilament network of claim 1 to an area in need of treatment.

### Claim 60 (depends on 59)

The method of claim 59 wherein the microfilament network is applied with the matrix.

### Claim 61 (depends on 59)

The method of claim 59 wherein the microfilament network is applied without the matrix.

### Claim 62 (depends on 59)

The method of claim 59 wherein the medical condition is a wound or an injured tissue.

### Claim 63 (depends on 59)

The method of claim 59 wherein the microfilament network prevents infection of the wound or the injured tissue, and facilitates wound healing and tissue regeneration.

### Claim 64 (depends on 59)

The method of claim 59, wherein the medical condition is a burn.

### Claim 65 (depends on 59)

The method of claim 59 including enhancing or promoting re-epithelialization of damaged skin.

### Claim 66 (depends on 59)

The method of claim 59, further including administering therapeutic drugs prior to, concurrent with or after applying the microfilament network to the area in need of treatment.

### Claim 67 (depends on 1)

A method of producing a continuous network of cell-derived microfilaments of claim 1 in vitro comprising:
culturing a plurality of cell clusters on a surface of a matrix substrate under conditions where the cell clusters produce microfilaments external to and surrounding the cell clusters, and wherein the extracellular microfilaments connect and form a continuous extracellular network of microfilaments between the cell clusters on the surface of the matrix substrate.

### Claim 68 (depends on 67)

The method of claim 67 wherein the cell clusters are spaced apart by an average distance of between about 1 microns and about 1000 microns.

### Claim 69 (depends on 67)

The method of claim 67 wherein the microfilaments connecting the cell clusters have an average length of between about 10 microns and about 100 microns.

### Claim 70 (depends on 67)

The method of claim 67 wherein the continuous extracellular microfilament network is a multilayered lattice.

### Claim 71 (depends on 67)

The method of claim 67 wherein the microfilaments are branched.

### Claim 72 (depends on 67)

The method of claim 67 wherein the continuous extracellular microfilament network is a multilayered lattice including long microfilaments having a length of between about 10 microns and about 1000 microns and short microfilaments having a length of between about 1 microns and about 10 microns.

### Claim 73 (depends on 67)

The method of claim 67 wherein the continuous extracellular network of microfilaments has a surface area of between about 0.01 cm2 and 500 cm2.

### Claim 74 (depends on 67)

The method of claim 67 wherein the continuous extracellular microfilament network is a mesh.

### Claim 75 (depends on 67)

The method of claim 67 wherein the continuous extracellular microfilament network is porous.

### Claim 76 (depends on 67)

The method of claim 67 wherein cells are implanted on the surface of the matrix substrate and wherein the cells migrate and aggregate into preclusters and proliferate to form the cell clusters.

### Claim 77 (depends on 67)

The method of claim 67 further including removing cell nuclei or the cell clusters from the continuous extracellular microfilament network.

### Claim 78 (depends on 67)

The method of claim 67 wherein the matrix substrate inhibits attachment of the cells.

### Claim 79 (depends on 67)

The method of claim 67 further including separating the matrix substrate from the continuous extracellular microfilament network.

### Claim 80 (depends on 1)

A method for facilitating wound repair and/or tissue regeneration comprising applying the microfilament network of claim 1 to a site in need thereof.

### Claim 81 (depends on 80)

The method of claim 80 wherein the microfilament network is applied with the matrix.

### Claim 82 (depends on 80)

The method of claim 80 wherein the microfilament network is applied without the matrix.

### Claim 83 (depends on 80)

The method of claim 80 wherein the microfilament network form square foot (ft2)-scale ultra-large microfilament lattices (UMLs).

### Claim 84 (depends on 83)

The method of claim 83 wherein the UMLs construct an environment for cell migration.

### Claim 85 (depends on 80)

The method of claim 80 wherein the microfilament network are multilayered and three dimensional (3D).

### Claim 86 (depends on 80)

The method of claim 80 including removing cell masses and producing acellular UMLs (AUMLs).

### Claim 87 (depends on 86)

The method of claim 86 wherein the AUMLs facilitate wound repair.

### Claim 88 (depends on 86)

The method of claim 86 including applying the AUMLs to a wounded site.

### Claim 89 (depends on 88)

The method of claim 88 wherein applying the AUMLs allows keratinocytes to engender large tunnels in the reepithelialized epidermis.

### Claim 90 (depends on 89)

The method of claim 89 wherein the large tunnels provide pathways for cells and nutrients to the site of wound repair.

### Claim 91 (depends on 80)

The method of claim 80 wherein the microfilament network prevents infection of the wounded site.

### Claim 92 (depends on 80)

The method of claim 80 including enhancing or promoting re-epithelialization of wounded skin.

### Claim 93 (depends on 80)

The method of claim 80 wherein the wound is second degree thermal burn wounds.

### Claim 94 (depends on 80)

The method of claim 80, further including administering therapeutic drugs prior to, concurrent with or after applying the microfilament network to the area in need of treatment.
